Rxi Pharmaceuticals (RXII) 2.19 $RXII RXi Pharm
Post# of 273257
Posted On: 09/04/2016 9:04:30 AM
Rxi Pharmaceuticals (RXII) 2.19 $RXII
RXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments
PR Newswire - Thu Aug 11, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the second quarter ended June 30, 2016, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Webcast Second Quarter 2016 Financial Results on Thursday, August 11, 2016
PR Newswire - Thu Jul 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will report its financial results for the second quarter ended June 30, 2016, and provide a business update on Thursday, August 11, 2016 after the close of the U.S. financial markets.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments
PR Newswire - Thu May 12, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today reported its financial results for the first quarter ended March 31, 2016, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Provides Strategic Update
PR Newswire - Tue May 10, 5:55AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it is in the process of exploring strategic options including a range of potential M&A and business development opportunities designed to enhance shareholder value. As part of this effort, RXi has engaged Griffin Securities, Inc. ("Griffin"
for one of these transactions.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, such as ALS (Lou Gehrig's Disease)
PR Newswire - Tue May 03, 6:12AM CDT
RXi Pharmaceuticals Corporation (RXi) (NASDAQ: RXII) and privately-held Thera Neuropharma, Inc. (Thera) announced today that they have entered into an exclusive license agreement for RXi's novel and proprietary sd-rxRNA® platform to develop therapeutics for neurodegenerative diseases.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Secures European Patent for Novel RNAi Platform
PR Newswire - Mon May 02, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has been granted a patent from the European Patent Office (EPO) for the composition of matter for its self-delivering RNAi platform (sd-rxRNA®). The Patent (EP 2 340 310 B1), titled "Reduced Size Self-Delivering RNAi Compounds" broadly covers the composition of RXi's sd-rxRNA platform and is not scheduled to expire until 2029.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
PR Newswire - Thu Apr 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials for dermal scarring and subretinal fibrosis associated with late stage AMD. Topical administration to the eye of the Company's novel self-delivering RNAi (sd-rxRNA®) technology formulated in a gel resulted in delivery throughout the cornea in the presence of a corneal wound in vivo.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation at the BioNetwork Partnering Summit
PR Newswire - Tue Apr 26, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the BioNetwork Partnering Summit on May 3, 2016 at 9:15 a.m. EDT. The Company has secured a premier presentation slot providing a platform to present to the industry's senior business development executives and institutional investors.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
PR Newswire - Tue Apr 19, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has received a Notice of Allowance, from the United States Patent and Trademark Office (USPTO), for both the composition of matter and methods of use for its self-delivering RNAi (sd-rxRNA®) compounds targeting connective tissue growth factor (CTGF). This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual Meeting
PR Newswire - Mon Apr 18, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting. This meeting is the largest gathering of eye and vision researchers in the world drawing 11,000 attendees exploring cutting-edge science. This year's conference will be held May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces Reverse Stock Split
PR Newswire - Fri Apr 15, 1:15PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 18, 2016, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "RXII," at the market open on April 18, 2016. The new CUSIP number for the Company's common stock following the reverse stock split will be 74979C501.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
PR Newswire - Thu Mar 31, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a patent covering methods for the treatment of compromised skin with self-delivering RNAi (sd-rxRNAs®) compounds targeting connective tissue growth factor (CTGF), including RXI-109, to prevent, reduce or inhibit dermal scarring. U.S. Patent #9,303,259, is scheduled to expire in 2029.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Recent Corporate Highlights
PR Newswire - Wed Mar 30, 3:05PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2015, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
PR Newswire - Mon Mar 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that Dr. Pamela Pavco, Chief Development Officer at RXi Pharmaceuticals, will present at the Oligonucleotide Therapeutics and Delivery Conference on Tuesday, April 5, 2016 at 4:45 p.m. EDT in Cambridge, Massachusetts.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Jan 26, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 2:30 p.m. ET in New York City.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
PR Newswire - Mon Dec 21, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 2 clinical trial in dermatology. The clinical study RXI-SCP-1502 will evaluate the safety and clinical activity of Samcyprone(TM) on the clearance of cutaneous warts.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016
PR Newswire - Mon Dec 14, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at a leading investor and partnering conference, the 8th Annual Biotech Showcase 2016, on Monday, January 11, 2016 at 9:30 a.m. PT in San Francisco, California.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Highlights
PR Newswire - Thu Nov 12, 3:05PM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today reported its financial results for the quarter ended September 30, 2015 and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for Retinal Scarring
PR Newswire - Thu Nov 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Webcast Third Quarter 2015 Financial Results on Thursday, November 12, 2015
PR Newswire - Thu Oct 29, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology today announced that it will report financial results for the third quarter ended September 30, 2015 on Thursday, November 12, 2015 after the close of the U.S. financial markets.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments
PR Newswire - Thu Aug 11, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the second quarter ended June 30, 2016, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Webcast Second Quarter 2016 Financial Results on Thursday, August 11, 2016
PR Newswire - Thu Jul 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will report its financial results for the second quarter ended June 30, 2016, and provide a business update on Thursday, August 11, 2016 after the close of the U.S. financial markets.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments
PR Newswire - Thu May 12, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today reported its financial results for the first quarter ended March 31, 2016, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Provides Strategic Update
PR Newswire - Tue May 10, 5:55AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced that it is in the process of exploring strategic options including a range of potential M&A and business development opportunities designed to enhance shareholder value. As part of this effort, RXi has engaged Griffin Securities, Inc. ("Griffin"
for one of these transactions. RXII: 2.19 (+0.15)
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, such as ALS (Lou Gehrig's Disease)
PR Newswire - Tue May 03, 6:12AM CDT
RXi Pharmaceuticals Corporation (RXi) (NASDAQ: RXII) and privately-held Thera Neuropharma, Inc. (Thera) announced today that they have entered into an exclusive license agreement for RXi's novel and proprietary sd-rxRNA® platform to develop therapeutics for neurodegenerative diseases.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Secures European Patent for Novel RNAi Platform
PR Newswire - Mon May 02, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has been granted a patent from the European Patent Office (EPO) for the composition of matter for its self-delivering RNAi platform (sd-rxRNA®). The Patent (EP 2 340 310 B1), titled "Reduced Size Self-Delivering RNAi Compounds" broadly covers the composition of RXi's sd-rxRNA platform and is not scheduled to expire until 2029.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
PR Newswire - Thu Apr 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that the Company has generated new data demonstrating corneal delivery of a fluorescent analog of RXI-109, the Company's most advanced clinical compound, currently in human clinical trials for dermal scarring and subretinal fibrosis associated with late stage AMD. Topical administration to the eye of the Company's novel self-delivering RNAi (sd-rxRNA®) technology formulated in a gel resulted in delivery throughout the cornea in the presence of a corneal wound in vivo.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation at the BioNetwork Partnering Summit
PR Newswire - Tue Apr 26, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the BioNetwork Partnering Summit on May 3, 2016 at 9:15 a.m. EDT. The Company has secured a premier presentation slot providing a platform to present to the industry's senior business development executives and institutional investors.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
PR Newswire - Tue Apr 19, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has received a Notice of Allowance, from the United States Patent and Trademark Office (USPTO), for both the composition of matter and methods of use for its self-delivering RNAi (sd-rxRNA®) compounds targeting connective tissue growth factor (CTGF). This patent includes the Company's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the skin and eye. The patent, once issued, will not expire until 2031.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016 Annual Meeting
PR Newswire - Mon Apr 18, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it will present at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting. This meeting is the largest gathering of eye and vision researchers in the world drawing 11,000 attendees exploring cutting-edge science. This year's conference will be held May 1-5, 2016 at the Washington State Convention Center in Seattle, Washington.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces Reverse Stock Split
PR Newswire - Fri Apr 15, 1:15PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 18, 2016, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "RXII," at the market open on April 18, 2016. The new CUSIP number for the Company's common stock following the reverse stock split will be 74979C501.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
PR Newswire - Thu Mar 31, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a patent covering methods for the treatment of compromised skin with self-delivering RNAi (sd-rxRNAs®) compounds targeting connective tissue growth factor (CTGF), including RXI-109, to prevent, reduce or inhibit dermal scarring. U.S. Patent #9,303,259, is scheduled to expire in 2029.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Recent Corporate Highlights
PR Newswire - Wed Mar 30, 3:05PM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2015, and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
PR Newswire - Mon Mar 28, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs, announced today that Dr. Pamela Pavco, Chief Development Officer at RXi Pharmaceuticals, will present at the Oligonucleotide Therapeutics and Delivery Conference on Tuesday, April 5, 2016 at 4:45 p.m. EDT in Cambridge, Massachusetts.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Jan 26, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 2:30 p.m. ET in New York City.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
PR Newswire - Mon Dec 21, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 2 clinical trial in dermatology. The clinical study RXI-SCP-1502 will evaluate the safety and clinical activity of Samcyprone(TM) on the clearance of cutaneous warts.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016
PR Newswire - Mon Dec 14, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at a leading investor and partnering conference, the 8th Annual Biotech Showcase 2016, on Monday, January 11, 2016 at 9:30 a.m. PT in San Francisco, California.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Highlights
PR Newswire - Thu Nov 12, 3:05PM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology, today reported its financial results for the quarter ended September 30, 2015 and provided a business update.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for Retinal Scarring
PR Newswire - Thu Nov 05, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
RXII: 2.19 (+0.15)
RXi Pharmaceuticals to Webcast Third Quarter 2015 Financial Results on Thursday, November 12, 2015
PR Newswire - Thu Oct 29, 6:02AM CDT
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology today announced that it will report financial results for the third quarter ended September 30, 2015 on Thursday, November 12, 2015 after the close of the U.S. financial markets.
RXII: 2.19 (+0.15)
(0)
(0)Scroll down for more posts ▼